Clinical Trials Logo

Filter by:
NCT ID: NCT03848832 Terminated - Rett Syndrome Clinical Trials

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

ARCH
Start date: July 29, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.

NCT ID: NCT03847090 Terminated - Clinical trials for Enteric Hyperoxaluria

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

URIROX-2
Start date: August 26, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.

NCT ID: NCT03844932 Terminated - Colitis, Ulcerative Clinical Trials

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Start date: January 24, 2019
Phase: Phase 2
Study type: Interventional

Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).

NCT ID: NCT03844152 Terminated - Healthy Clinical Trials

RIGHTWHEY - Responders In Gut HealTh Markers Using Fermented WHEY

RIGHTWHEY
Start date: March 13, 2019
Phase: N/A
Study type: Interventional

This 8-week intervention will investigate the effect of daily consumption of a fermented whey concentrate on the short-chain fatty acid profile of faeces in healthy individuals. This study will help us understand if consumption of fermented foods rich in lactic acid have a beneficial effect on gut health.

NCT ID: NCT03843125 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

SLE-BRAVE-X
Start date: September 9, 2019
Phase: Phase 3
Study type: Interventional

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

NCT ID: NCT03841448 Terminated - Clinical trials for Glomerulonephritis, IgA

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

Start date: September 30, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.

NCT ID: NCT03839901 Terminated - Wrist Sprain Clinical Trials

Rehabilitation Programmes for Scapholunate Instability

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Two different exercises approaches were tested in patients with Scapho-Lunate (SL) instability; one to strengthen the tendons in static positions and the other to strengthen the tendons whilst the wrist is moving.

NCT ID: NCT03836716 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.

NCT ID: NCT03834220 Terminated - Solid Tumor Clinical Trials

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Start date: March 22, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

NCT ID: NCT03833258 Terminated - Clinical trials for Total Hip Replacement

Unrestricted Rehabilitation Pathway Following Total Hip Replacement

ReHip2
Start date: August 22, 2019
Phase: N/A
Study type: Interventional

The purpose of ReHip2 is to explore the impact on function and quality of life in patients following Total Hip Replacement (THR). A randomised controlled trial will compare two different rehabilitation pathways following surgery (Routine care with precautions and Treatment group with no precautions). The proposal is to carry out the RCT with a minimum of 182 patients based in the UK.